MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ
0.1401
-0.0141
-9.14%
Opening 12:58 08/17 EDT
OPEN
0.1545
PREV CLOSE
0.1542
HIGH
0.1556
LOW
0.1400
VOLUME
17.62M
TURNOVER
--
52 WEEK HIGH
3.870
52 WEEK LOW
0.1138
MARKET CAP
68.49M
P/E (TTM)
-0.1790
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GOSS last week (0810-0814)?
Weekly Report · 6h ago
Gossamer Bio Price Target Cut to $4.00/Share From $15.00 by Piper Sandler
Dow Jones · 3d ago
Gossamer Bio Is Maintained at Overweight by Piper Sandler
Dow Jones · 3d ago
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), Nektar Therapeutics (NKTR) and Aprea Therapeutics (APRE)
TipRanks · 3d ago
Guggenheim Remains a Hold on Gossamer Bio (GOSS)
TipRanks · 3d ago
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
NASDAQ · 3d ago
Gossamer Bio GAAP EPS of -$0.08 beats by $0.06, revenue of $9.24M beats by $5.61M
Seeking Alpha · 3d ago
More
About GOSS
Gossamer Bio, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The Company's lead product candidate is Seralutinib (GB002), is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR. Seralutinib is designed to inhibit multiple kinases in the pathology of PAH. The PDGFR is a tyrosine kinase receptor which, when activated by its agonist, induces cellular proliferation. The c-KIT pathway was also identified as a factor involved in pulmonary vascular remodeling, particularly in the cells implicated in perivascular inflammation.

Webull offers Gossamer Bio Inc stock information, including NASDAQ: GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.